CytomX Therapeutics, Inc.
NASDAQ:CTMXBiotechnology
-$0.03 today
- Market cap
- $409.85M
- Beta
- 2.09
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.33
Volume 4.39M
Average 4.99M
CTMX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
CytomX Therapeutics, Inc.NASDAQ: CTMX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $10.69M rose 13.4% year over year, ahead of the -1.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 45.3% from the prior quarter. Over 3 fiscal years it compounded at -11.4% a year.
Context
- Selling, general & admin amounted to 39.2% of revenue in FY2025, up 17.6 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $12.12M (-59.4%) for the fiscal year ending Dec 2026, a slowdown from the +0.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $10.69M+45.3% QoQ
- Last fiscal yearDec 2025
- $29.84M+0.4% YoY
- LTMMar 2026
- $31.1M-1.0% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 29.84M USD
- Year-over-year change
- +0.4%
- 4-year CAGR
- -6.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.84M | +0.4% |
| FY2024 | 2024-12-31 | 29.73M | -1.0% |
| FY2023 | 2023-12-31 | 30.02M | -29.9% |
| FY2022 | 2022-12-31 | 42.85M | +9.4% |
| FY2021 | 2021-12-31 | 39.16M | — |
Selling, General & Admin vs competitors
How CTMX compares with its peers on the latest reported figures
- CTMX's LTM Mar 2026 selling, general & admin of $31.1M is the 8th highest of the 10 companies compared; the peer median is $51.3M.
- Its year-over-year change of -1.0% is the 6th highest of 9, against a peer median of +13.4%.
- Selling, general & admin amounts to 87.5% of revenue for CTMX, versus a peer median of 103.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $15.14B | +24248.6% | -5.7% | 5694.1% | |
| LTM Mar 2026 | $82.03M | +32.5% | — | 103.6% | |
| LTM Aug 2026 | $78.21M | +57.0% | +11.6% | 11.1% | |
| LTM Jun 2026 | $65.29M | +5.1% | +10.3% | 62.2% | |
| LTM Sep 2026 | $51.3M | +21.7% | +17.2% | 45802.7% | |
| LTM Mar 2026 | $38.15M | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $35.33M | -27.9% | -11.7% | 35.5% | |
| LTM Mar 2026 | $31.1M | -1.0% | -11.4% | 87.5% | |
| LTM Mar 2026 | $20.02M | -13.1% | -15.9% | 144.4% | |
| LTM Jun 2024 | $7.81M | — | -15.8% | 957.8% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CTMX) | $51.3M | +13.4% | -8.7% | 103.6% | |
Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 114.19M | 111.65M | 77.68M | 83.38M | 68.73M |
| Selling, General & Admin | 39.16M | 42.85M | 30.02M | 29.73M | 29.84M |
| Operating Expenses | 153.35M | 154.5M | 107.7M | 113.11M | 98.57M |
| Depreciation & Amortization | 2.71M | 2.44M | 2.18M | 1.77M | 1.38M |
| EBITDA | (113.16M) | (96.87M) | 5.5M | 33.86M | (15.75M) |
| EBITDA Margin | -303.3% | -182.2% | 5.4% | 24.5% | -20.7% |
| Operating Income | (116.04M) | (101.34M) | (6.48M) | 25M | (22.36M) |
| Operating Margin | -311.0% | -190.6% | -6.4% | 18.1% | -29.3% |
| Interest Income | 255K | 1.68M | 9.84M | 7.14M | 5.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 172K | 2.02M | 9.81M | 7.1M | 5.23M |
| Income Before Tax | (115.87M) | (99.32M) | 3.32M | 32.09M | (17.13M) |
| Pre-Tax Margin | -310.5% | -186.8% | 3.3% | 23.2% | -22.5% |
| Income Tax Expense | 0 | 0 | 3.89M | 224K | 238K |
| Net Income | (115.87M) | (99.32M) | (569K) | 31.87M | (17.37M) |
| Net Margin | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% |
| EPS (Basic) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| EPS (Diluted) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| Weighted Avg Shares | 64.15M | 65.74M | 73.81M | 84.44M | 137.94M |
| Weighted Avg Shares (Diluted) | 64.15M | 65.74M | 73.81M | 84.75M | 137.94M |
CytomX Therapeutics, Inc.
NASDAQ:CTMX
Intrinsic Alpha fair value
Locked
Current Price
$1.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.